Long-term symptoms after SARS-CoV-2 infection in a cohort of people living with HIV.
COVID-19
HIV
Long-COVID
PLWH
Post-COVID-19 conditions
Post-acute sequelae of SARS-CoV-2
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
03 May 2024
03 May 2024
Historique:
received:
14
02
2024
accepted:
26
04
2024
medline:
3
5
2024
pubmed:
3
5
2024
entrez:
3
5
2024
Statut:
aheadofprint
Résumé
Our Hospital in Northern Italy assists 3817 people living with HIV (PLWH) and has faced the impact of COVID-19. Little is known about the impact of HIV infection on the risk of post-COVID-19 conditions (PCCs) onset. We aim to assess the incidence of PCC in PLWH and the factors associated with its occurrence. We performed a retrospective, observational study including all PLWH > 18 years registered in the Brescia Health Protection Agency database, assessing SARS-CoV-2 burden, vaccination status, socio-demographic, and viro-immunological parameters from February 2020 until May 2022. Persistence of self-reported symptoms (clustered into gastrointestinal, respiratory, osteo-muscular, and neuro-behavioral symptoms) was evaluated after 3 months by a telephone-administered questionnaire. We estimated the associations between all variables and outcomes through univariate and multivariable logistic models. In the study period, 653 PLWH were diagnosed with SARS-CoV-2 infection (17.1%). We observed 19 (2.9%) reinfections, 71 (10.9%) hospitalizations, and 3 (0.5%) deaths. We interviewed 510/653 PLWH (78%), and 178 (PCCs prevalence 34.9%; CI 95% 30.7-39.2) reported persistent symptoms. Asthenia/fatigue was the most reported symptom (60/178), followed by muscular pain (54/178). In the multivariate regression model, there was a lower risk of PCCs in males respect to females (adjusted OR = 0.64; CI 95% 0.99-3.66), while hospitalization during acute infection was associated with an increased the risk of PCCs (adjusted OR = 1.9; CI 95% 0.99-3.66). Notably, no viro-immunological variable modified the PCCs risk onset. Our study highlights a substantial prevalence of PCCs among PLWH, three months post-SARS-CoV-2 infection, independent of viro-immunological features or vaccination status.
Sections du résumé
BACKGROUND
BACKGROUND
Our Hospital in Northern Italy assists 3817 people living with HIV (PLWH) and has faced the impact of COVID-19. Little is known about the impact of HIV infection on the risk of post-COVID-19 conditions (PCCs) onset. We aim to assess the incidence of PCC in PLWH and the factors associated with its occurrence.
METHODS
METHODS
We performed a retrospective, observational study including all PLWH > 18 years registered in the Brescia Health Protection Agency database, assessing SARS-CoV-2 burden, vaccination status, socio-demographic, and viro-immunological parameters from February 2020 until May 2022. Persistence of self-reported symptoms (clustered into gastrointestinal, respiratory, osteo-muscular, and neuro-behavioral symptoms) was evaluated after 3 months by a telephone-administered questionnaire. We estimated the associations between all variables and outcomes through univariate and multivariable logistic models.
RESULTS
RESULTS
In the study period, 653 PLWH were diagnosed with SARS-CoV-2 infection (17.1%). We observed 19 (2.9%) reinfections, 71 (10.9%) hospitalizations, and 3 (0.5%) deaths. We interviewed 510/653 PLWH (78%), and 178 (PCCs prevalence 34.9%; CI 95% 30.7-39.2) reported persistent symptoms. Asthenia/fatigue was the most reported symptom (60/178), followed by muscular pain (54/178). In the multivariate regression model, there was a lower risk of PCCs in males respect to females (adjusted OR = 0.64; CI 95% 0.99-3.66), while hospitalization during acute infection was associated with an increased the risk of PCCs (adjusted OR = 1.9; CI 95% 0.99-3.66). Notably, no viro-immunological variable modified the PCCs risk onset.
CONCLUSIONS
CONCLUSIONS
Our study highlights a substantial prevalence of PCCs among PLWH, three months post-SARS-CoV-2 infection, independent of viro-immunological features or vaccination status.
Identifiants
pubmed: 38700658
doi: 10.1007/s15010-024-02288-9
pii: 10.1007/s15010-024-02288-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Larsen NW, Stiles LE, Miglis MG. Preparing for the long-haul: autonomic complications of COVID-19. Auton Neurosci. 2021;235:102841.
doi: 10.1016/j.autneu.2021.102841
pubmed: 34265539
pmcid: 8254396
World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus [Internet]. 2021 Oct. Report No.: WHO/2019-nCoV/Post_COVID-19_condition/Clinical_case_definition/2021.1. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1
Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226:1593–607.
doi: 10.1093/infdis/jiac136
pubmed: 35429399
Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens De Noordhout C, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022;54:1473–87.
doi: 10.1080/07853890.2022.2076901
pubmed: 35594336
pmcid: 9132392
Moyo E, Chimene M, Moyo P, Musuka G, Mangoya D, Murewanhema G, et al. Risk factors and clinical presentations of long COVID in Africa: a scoping review. J Infect Public Health. 2023;16:1982–8.
doi: 10.1016/j.jiph.2023.09.021
pubmed: 37890221
Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et al. Risk factors associated with post−COVID-19 condition: a systematic review and meta-analysis. JAMA Intern Med. 2023;183:566.
doi: 10.1001/jamainternmed.2023.0750
pubmed: 36951832
pmcid: 10037203
Turtle L, Thorpe M, Drake TM, Swets M, Palmieri C, Russell CD, et al. Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study. PLOS Med. 2023;20:e1004086.
doi: 10.1371/journal.pmed.1004086
pubmed: 36719907
pmcid: 9928075
Kamanzi P, Mulundu G, Mutale K, Mumba C, Ngalamika O. HIV and inflammatory markers are associated with persistent COVID-19 symptoms. Immun Inflamm Dis. 2023;11:e859.
doi: 10.1002/iid3.859
pubmed: 37249281
pmcid: 10165949
Istituto Superiode di Sanità (ISS), EpiCentro. EpiCentro, L’epidemiologia per la sanità pubblica. Monitoraggio delle varianti del virus SARS-CoV-2 di interesse in sanità pubblica in Italia - Archivio dei rapporti periodici. https://www.epicentro.iss.it/coronavirus/sars-cov-2-monitoraggio-varianti-rapporti-periodici
Istituto Superiore di Sanità (ISS), EpiCentro. Prevalenza e distribuzione delle varianti di SARS-CoV-2 di interesse per la sanità pubblica in Italia [Internet]. 2022 Jan. Report No.: 16. https://www.epicentro.iss.it/coronavirus/pdf/sars-cov-2-monitoraggio-varianti-rapporti-periodici-19-gennaio-2022.pdf
Mannucci PM, Galbussera AA, D’Avanzo B, Tettamanti M, Remuzzi G, Fortino I, et al. Two years of SARS-CoV-2 pandemic and COVID-19 in Lombardy. Italy Intern Emerg Med. 2023;18:1445–51.
doi: 10.1007/s11739-023-03315-7
pubmed: 37314640
Tiecco G, Storti S, Degli Antoni M, Focà E, Castelli F, Quiros-Roldan E. Omicron genetic and clinical peculiarities that may overturn SARS-CoV-2 pandemic: a literature review. Int J Mol Sci. 2022;23:1987.
doi: 10.3390/ijms23041987
pubmed: 35216104
pmcid: 8876558
Ministero della Salute, Istituto Superiore di Sanità. Report 89 Sintesi nazionale Monitoraggio Fase 2 (DM Salute 30 aprile 2020) [Internet]. 2021 Jan. Report No.: 89. https://www.salute.gov.it/portale/nuovocoronavirus/dettaglioMonitoraggioNuovoCoronavirus.jsp?lingua=italiano&menu=monitoraggi&id=99
Centers for Disease Control and Prevention. cdc.gov. COVID-19 Vaccines for Specific Groups of People. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/specific-groups.html
Maifredi G, Izzo I, Gasparotti C, Sileo CV, Castelli F, HIV-CoV Group, et al. SARS-CoV-2 Infection and Vaccination Coverage among Fragile Populations in a Local Health Area of Northern Italy. Life. 2022;12:1009.
doi: 10.3390/life12071009
pubmed: 35888096
pmcid: 9316873
Quiros-Roldan E, Magro P, Carriero C, Chiesa A, El Hamad I, Tratta E, et al. Consequences of the COVID-19 pandemic on the continuum of care in a cohort of people living with HIV followed in a single center of Northern Italy. AIDS Res Ther. 2020;17:59.
doi: 10.1186/s12981-020-00314-y
pubmed: 33012282
pmcid: 7533114
Höft MA, Burgers WA, Riou C. The immune response to SARS-CoV-2 in people with HIV. Cell Mol Immunol. 2023;21:184–96.
doi: 10.1038/s41423-023-01087-w
pubmed: 37821620
pmcid: 10806256
Nguyen VT, Nagavedu K, Morrison M, Chen T, Randall LM, Landazabal C, et al. COVID-19 severity in people with HIV compared to those without HIV. J Acquir Immune Defic Syndr. 1999. https://doi.org/10.1097/QAI.0000000000003378 .
doi: 10.1097/QAI.0000000000003378
pubmed: 10534150
Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4:e2128568.
doi: 10.1001/jamanetworkopen.2021.28568
pubmed: 34643720
pmcid: 8515212
Kahlert CR, Strahm C, Güsewell S, Cusini A, Brucher A, Goppel S, et al. Post-acute sequelae after severe acute respiratory syndrome coronavirus 2 infection by viral variant and vaccination status: a multicenter cross-sectional study. Clin Infect Dis. 2023;77:194–202.
doi: 10.1093/cid/ciad143
pubmed: 36905145
pmcid: 10371307
Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, et al. Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA. 2022;328:676.
doi: 10.1001/jama.2022.11691
pubmed: 35796131
pmcid: 9250078
Ballouz T, Menges D, Kaufmann M, Amati R, Frei A, Von Wyl V, et al. Post COVID-19 condition after wildtype, delta, and omicron SARS-CoV-2 infection and prior vaccination: pooled analysis of two population-based cohorts. PLOS One. 2023;18:e0281429.
doi: 10.1371/journal.pone.0281429
pubmed: 36812215
pmcid: 9946205
Marra AR, Kobayashi T, Callado GY, Pardo I, Gutfreund MC, Hsieh MK, et al. The effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions: a systematic literature review and meta-analysis of the latest research. Antimicrob Steward Healthc Epidemiol. 2023;3:e168.
doi: 10.1017/ash.2023.447
pubmed: 38028898
pmcid: 10644173
Hastie CE, Lowe DJ, McAuley A, Mills NL, Winter AJ, Black C, et al. True prevalence of long-COVID in a nationwide, population cohort study. Nat Commun. 2023;14:7892.
doi: 10.1038/s41467-023-43661-w
pubmed: 38036541
pmcid: 10689486
Peluso MJ, Spinelli MA, Deveau TM, Forman CA, Munter SE, Mathur S, et al. Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection. AIDS. 2022;36:F7-16.
doi: 10.1097/QAD.0000000000003338
pubmed: 35866847
Almomen A, Cox J, Lebouché B, Cheng MP, Frenette C, Routy JP, et al. Short communication: ongoing impact of the social determinants of health during the second and third waves of the COVID-19 pandemic in people living with hiv receiving care in a montreal-based tertiary care center. AIDS Res Hum Retroviruses. 2022;38:359–62.
doi: 10.1089/aid.2021.0186
pubmed: 35172609
Jassat W, Mudara C, Vika C, Welch R, Arendse T, Dryden M, et al. A cohort study of post-COVID-19 condition across the beta, delta, and omicron waves in South Africa: 6-month follow-up of hospitalized and nonhospitalized participants. Int J Infect Dis. 2023;128:102–11.
doi: 10.1016/j.ijid.2022.12.036
pubmed: 36587841
pmcid: 9800016
Karuna S, Gallardo-Cartagena JA, Theodore D, Hunidzarira P, Montenegro-Idrogo J, Hu J, et al. Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global region. J Glob Health. 2023;23:06020.
doi: 10.7189/jogh.13.06020
Mazzitelli M, Trunfio M, Sasset L, Leoni D, Castelli E, Lo Menzo S, et al. Factors associated with severe COVID-19 and post-acute COVID-19 syndrome in a cohort of people living with HIV on antiretroviral treatment and with undetectable HIV RNA. Viruses. 2022;14:493.
doi: 10.3390/v14030493
pubmed: 35336900
pmcid: 8954437
Peluso MJ, Deveau TM, Munter SE, Ryder D, Buck A, Beck-Engeser G, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest. 2023;133:e163669.
doi: 10.1172/JCI163669
pubmed: 36454631
pmcid: 9888380
Pujari S, Gaikwad S, Chitalikar A, Dabhade D, Joshi K, Bele V. Long-coronavirus disease among people living with HIV in western India: an observational study. Immun Inflamm Dis. 2021;9:1037–43.
doi: 10.1002/iid3.467
pubmed: 34078004
pmcid: 8239760
Yue Y, Liang C, Weissman S, Lyu T, Olatosi B, Li X. 12-MONTH CONSEQUENCES IN PEOPLE WITH HIV/SARS-CoV-2 COINFECTION: NATIONAL EHR COHORT. CROI 2023 Abstr Ebook [Internet]. 884. https://www.croiconference.org/croi-2023-resources/
Durstenfeld MS, Peluso MJ, Spinelli MA, Li D, Sander E, Swaminathan S, Arechiga V, Hoh R,, Aras MA, Long CS, Deeks SG, Hsue P. EXERCISE CAPACITY IS REDUCED IN HIV INDEPENDENT OF SARS-CoV-2 INFECTION. CROI 2023 Abstr Ebook [Internet]. 2023;666. https://www.croiconference.org/croi-2023-resources/
Yendewa GA, Perez JA, Patil N, McComsey GA. HIV INFECTION INCREASES RISK OF PASC WHILE COVID-19 VACCINATION IS PROTECTIVE. CROI 2023 Abstr Ebook. 724.
Antar A, Gallego Marquez N, Jamal A, Alisha Dziarski A, Fu J, Walch S, Romero A, Queiroz A, Araujo-Pereira M, Zelaya A, Akasreku E, Andrade B, Peluso M, Landay A. SYMPTOMS AND BIOMARKERS OF LONG COVID IN PEOPLE LIVING WITH AND WITHOUT HIV. CROI 2023 Abstract ebook [Internet]. 2023; https://www.croiconference.org/croi-2023-resources/